Society of Gynaecological Oncology Congress 2026: Taliya Lantsman, MD | Dana-Farber Cancer Institute
New research from Dana-Farber's Taliya Lantsman, MD, presented at #SGO26 shows a single institution experience of trastuzumab deruxtecan (T-DXd) in relation to HER2 expression in advanced gynecologic malignancies.
🎬 More from Dana-Farber Cancer Institute
Understanding Chemo Neuropathy: A Webinar by the Older Adults with GI Cancer Program | Dana-Farber
19 views
Learning About Chronic Lymphocytic Leukemia | Lymph Notes: A Lymphoma Learning Series
112 views
ASCO26: David Reardon, MD Glioblastoma Vaccine | Dana-Farber Cancer Institute
106 views
Society of Gynaecological Oncology Congress 2026: Tara Berman, MD | Dana-Farber Cancer Institute
30 views
ASCO26: Julia Rotow, MD Silevertinib in Lung Cancer | Dana-Farber Cancer Institute
55 views
ASCO26: Atish Choudhury, MD, PhD A-DREAM/Alliance A032101 | Dana-Farber Cancer Institute
38 views